Your browser doesn't support javascript.
loading
Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel.
Melody, Megan; Gandhi, Sangeetha; Rahman, Zaid Abdel; Lengerke-Diaz, Paula; Gannon, Nicole; Rosenthal, Allison; Truong, Tuan; Novo, Mattia; Brandes, Eva; Lange, Gina; Estby, Breana; Johnston, Patrick; Ansell, Steve; Bennani, N Nora; Paludo, Jonas; Bisneto, Jose Villasboas; Ayala, Ernesto; Tun, Han W; Murthy, Hemant S; Roy, Vivek; Foran, James; Castro, Januario; Lin, Yi; Kharfan-Dabaja, Mohamed A.
Afiliación
  • Melody M; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
  • Gandhi S; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Rahman ZA; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Lengerke-Diaz P; Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA.
  • Gannon N; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Rosenthal A; Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA.
  • Truong T; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Novo M; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Brandes E; Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy.
  • Lange G; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Estby B; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Johnston P; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Ansell S; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Bennani NN; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Paludo J; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Bisneto JV; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Ayala E; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Tun HW; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Murthy HS; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Roy V; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Foran J; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Castro J; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
  • Lin Y; Division of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USA.
  • Kharfan-Dabaja MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Eur J Haematol ; 107(1): 48-53, 2021 Jul.
Article en En | MEDLINE | ID: mdl-33655560
INTRODUCTION: Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if axicabtagene ciloleucel (axi-cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B-cell lymphoma. METHODS: We conducted a retrospective analysis across three Mayo Clinic centers to assess the relationship of hypoalbuminemia (defined as a serum albumin (SA) levels ≤ 3.5 g/dL) on outcomes of patients treated with axi-cel. RESULTS: This analysis included 81 patients. Two patients had no available SA levels preceding axi-cel infusion. Eighteen patients (22.8%) had hypoalbuminemia with a median SA of 3.3 g/dL. Patients with normal SA had a statistically higher ORR than those without hypoalbuminemia (P = .018). There was no difference in 1-year PFS and OS between the group with hypoalbuminemia and the group with normal SA levels (48% vs 49%, P = .81) and (74% vs 73%, P = .97), respectively. There was no difference in the severity or median duration of cytokine release syndrome or neurotoxicity between the two groups. CONCLUSION: Notwithstanding the limitations related to the relatively small sample size, axi-cel therapy appears to overcome the adverse effect of hypoalbuminemia on OS and PFS. Large multicenter clinical studies are certainly needed to validate these findings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Linfoma de Células B Grandes Difuso / Antígenos CD19 / Hipoalbuminemia / Síndrome de Liberación de Citoquinas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Linfoma de Células B Grandes Difuso / Antígenos CD19 / Hipoalbuminemia / Síndrome de Liberación de Citoquinas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido